Literature DB >> 20652951

Limited resection followed by intraoperative seed implantation is comparable to stereotactic body radiotherapy for solitary lung cancer.

Bhupesh Parashar1, Priti Patel, Stefano Monni, Prabhsimranjot Singh, Nikki Sood, Samuel Trichter, Albert Sabbas, A Gabriella Wernicke, Dattatreyudu Nori, K S Clifford Chao.   

Abstract

BACKGROUND: The objective of this study was to compare the outcomes of patients who underwent wedge resection plus intraoperative brachytherapy versus patients who received stereotactic body radiotherapy (SBRT) for single malignant lung nodules.
METHODS: A retrospective chart review included 55 patients who were treated for single lung nodules, and 47 of those patients who had adequate information were chosen for the current analysis. Twenty-five patients with single malignant lung nodules received SBRT. Twenty-two patients underwent limited surgical resection plus radioactive seed implantation for solitary malignant lung nodules.
RESULTS: Univariate statistical analysis demonstrated a significance difference only for age in the 2 groups: The mean age in the radioactive seed group (66.6 years) was statistically significantly different from the mean of the age in the SBRT group (75.9 years; 2-sided P=.04). No significant differences were observed between the 2 groups in terms of local control, distant metastasis, survival, or toxicity.
CONCLUSIONS: The current results demonstrated comparable efficacy in outcome and toxicity between surgical resection with radioactive seed implantation and SBRT for the treatment of single malignant lung nodules in patients who were not candidates for lobectomy/pneumonectomy.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20652951     DOI: 10.1002/cncr.25441

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes.

Authors:  Bhupesh Parashar; Prabhsimranjot Singh; Paul Christos; Shruthi Arora; Prashant Desai; A Gabriella Wernicke; Marylynn Delamerced; Dustin Boothe; Dattatreyudu Nori; Ksc Chao
Journal:  J Radiosurg SBRT       Date:  2013

2.  Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future?

Authors:  Luca Bertolaccini; Alberto Terzi; Francesco Ricchetti; Filippo Alongi
Journal:  Ann Transl Med       Date:  2015-02

Review 3.  Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients.

Authors:  Guy C Jones; Jason D Kehrer; Jenna Kahn; Bobby N Koneru; Ram Narayan; Tarita O Thomas; Kevin Camphausen; Minesh P Mehta; Aradhana Kaushal
Journal:  Clin Lung Cancer       Date:  2015-04-23       Impact factor: 4.785

4.  Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes.

Authors:  Bhupesh Parashar; Prabhsimranjot Singh; Paul Christos; Shruthi Arora; Prashant Desai; A Gabriella Wernicke; Marylynn Delamerced; Dustin Boothe; Dattatreyudu Nori; Ksc Chao
Journal:  J Radiosurg SBRT       Date:  2013

5.  Impact of target area selection in 125 Iodine seed brachytherapy on locoregional recurrence in patients with non-small cell lung cancer.

Authors:  Wei-Liang Yan; Jin-Shuang Lv; Zhi-Yu Guan; Li-Yang Wang; Jing-Kui Yang; Ji-Xiang Liang
Journal:  Thorac Cancer       Date:  2017-02-20       Impact factor: 3.500

Review 6.  Sublobar resection is associated with improved outcomes over radiotherapy in the management of high-risk elderly patients with Stage I non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Huan-Huan Wang; Chun-Ze Zhang; Bai-Lin Zhang; Jie Chen; Xian-Liang Zeng; Lei Deng; Mao-Bin Meng
Journal:  Oncotarget       Date:  2017-01-24

7.  Chinese Expert Consensus Workshop Report: Guideline for permanent iodine-125 seed implantation of primary and metastatic lung tumors.

Authors:  Fujun Zhang; Junjie Wang; Jinhe Guo; Yuliang Li; Xuequan Huang; Zhiyu Guan; Guangyan Lei; Juan Wang; Xin Ye; Xiaogang Zhao; Jing Wang; Ruoyu Wang; Bin Liu
Journal:  Thorac Cancer       Date:  2018-12-06       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.